Bicocca Open Archive

Logo unimib boa
CIARDULLO, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.060
AS - Asia 5.693
EU - Europa 3.421
SA - Sud America 987
AF - Africa 182
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.637
SG - Singapore 2.090
CN - Cina 1.108
IT - Italia 938
HK - Hong Kong 757
BR - Brasile 731
VN - Vietnam 703
RU - Federazione Russa 616
DE - Germania 459
CA - Canada 346
SE - Svezia 306
IE - Irlanda 267
GB - Regno Unito 193
IN - India 187
FR - Francia 159
BD - Bangladesh 146
KR - Corea 126
AR - Argentina 105
ID - Indonesia 105
NL - Olanda 83
FI - Finlandia 77
IQ - Iraq 77
TR - Turchia 54
ZA - Sudafrica 54
JP - Giappone 51
PK - Pakistan 49
CH - Svizzera 48
UA - Ucraina 47
MX - Messico 45
ES - Italia 44
PL - Polonia 42
SA - Arabia Saudita 42
EC - Ecuador 38
AU - Australia 35
PH - Filippine 34
CO - Colombia 33
AT - Austria 31
EG - Egitto 31
VE - Venezuela 23
UZ - Uzbekistan 22
BE - Belgio 21
MA - Marocco 18
DK - Danimarca 16
JO - Giordania 16
TW - Taiwan 15
IR - Iran 14
MY - Malesia 14
PY - Paraguay 14
CL - Cile 13
DZ - Algeria 13
AE - Emirati Arabi Uniti 12
RO - Romania 12
KE - Kenya 11
OM - Oman 11
PE - Perù 10
PT - Portogallo 10
UY - Uruguay 10
NP - Nepal 9
TH - Thailandia 9
BG - Bulgaria 8
BO - Bolivia 8
ET - Etiopia 8
LT - Lituania 8
NG - Nigeria 8
PA - Panama 8
CZ - Repubblica Ceca 7
TN - Tunisia 7
AZ - Azerbaigian 6
IL - Israele 6
KZ - Kazakistan 6
SN - Senegal 6
DO - Repubblica Dominicana 5
AL - Albania 4
BY - Bielorussia 4
GR - Grecia 4
LB - Libano 4
NI - Nicaragua 4
PS - Palestinian Territory 4
ZM - Zambia 4
AO - Angola 3
BW - Botswana 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
NO - Norvegia 3
ZW - Zimbabwe 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CR - Costa Rica 2
CY - Cipro 2
GD - Grenada 2
HU - Ungheria 2
JM - Giamaica 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
SO - Somalia 2
Totale 16.357
Salva come PNG Salva come JPEG
Città #
Singapore 1.202
Hong Kong 731
Ann Arbor 702
Ashburn 544
San Jose 463
Santa Clara 306
Frankfurt am Main 286
New York 259
Dublin 256
Chicago 252
Toronto 247
Milan 240
Hefei 238
Ho Chi Minh City 206
Beijing 202
Chandler 201
Los Angeles 179
Fairfield 175
Dallas 165
Hanoi 152
Seoul 105
The Dalles 103
Wilmington 102
Princeton 96
Lauterbourg 86
Seattle 81
Houston 79
Jakarta 71
Woodbridge 71
Cambridge 67
London 65
São Paulo 62
Altamura 58
Moscow 57
Council Bluffs 56
Munich 53
Shanghai 52
Rome 51
Buffalo 48
Helsinki 48
Lawrence 47
Zurich 44
San Diego 36
Orem 34
Montreal 33
Da Nang 32
Atlanta 31
Baghdad 31
Boardman 31
Haiphong 30
Tokyo 27
Bari 26
Warsaw 26
San Francisco 25
Dong Ket 24
Nuremberg 24
Guangzhou 23
Brooklyn 22
Monza 22
Rio de Janeiro 22
Phoenix 21
Biên Hòa 20
Nanjing 20
Riyadh 20
Tashkent 20
Kent 19
Denver 18
Hải Dương 18
Johannesburg 18
Lappeenranta 18
Mumbai 18
Quito 18
Brussels 17
Dhaka 17
Stockholm 17
Boston 16
Kocaeli 15
Porto Alegre 15
Pune 15
Sydney 15
Vienna 15
Amman 14
Amsterdam 14
Brasília 14
Chennai 14
Naples 14
Belo Horizonte 13
Cairo 13
Cape Town 13
Istanbul 13
Melbourne 13
Mexico City 13
New Delhi 13
Salvador 13
Curitiba 12
Erbil 12
Hyderabad 12
Jeddah 12
Manchester 12
Salt Lake City 12
Totale 9.623
Salva come PNG Salva come JPEG
Nome #
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction 602
Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? 455
Exploring the landscape of steatotic liver disease in the general US population 430
Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States 423
Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi-centre cross-sectional study 405
Endocrinology and Metabolic Diseases (Including Diabetes) 338
Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy 281
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes 255
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting 235
Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes 230
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions 218
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes 216
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes 208
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes 207
Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes 205
Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence 199
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes 198
Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients 197
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 194
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 193
Time trends in liver-related mortality in people with and without diabetes: Results from a population based study 192
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications 191
Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study 191
Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD 187
Lack of awareness of liver organ damage in patients with type 2 diabetes 183
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population 183
Development of a new model of insulin sensitivity in patients with type 2 diabetes and association with mortality 181
Baseline TSH levels and short-term weight loss after different procedures of bariatric surgery 181
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes 180
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment 179
Metabolic and psychological features are associated with weight loss 12 months after sleeve gastrectomy 178
Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort 174
Preferences, Expectations and Attitudes on Basal Insulin from Patient–Physician–Payer Perspective: A Multi-stakeholder Survey by the Italian Diabetes Society (ITA4P Study) 174
Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey 174
Authors' response to Guo, Wei et al. 173
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study 171
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population 168
Authors' reply to Zou et al 167
Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy 165
Impact of the duration of type 2 diabetes on the screening for nonal- coholic fatty liver disease and advanced fibrosis 165
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population 165
An unexpected bilateral mass after total thyroidectomy 164
NAIF: A novel artificial intelligence-based tool for accurate diagnosis of stage F3/F4 liver fibrosis in the general adult population, validated with three external datasets 161
Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories 160
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting 160
Evaluating the Prognostic Value of the Triglyceride–Glucose Index in Different Populations: A Critical Analysis 156
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 156
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016 155
Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population 155
Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study 154
Risk stratification tools for heart failure in the diabetes clinic 154
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines 154
Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus 154
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 153
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes 151
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 150
Medication Use Before and After Different Bariatric Surgery Procedures: Results from a Population-Based Cohort Study 149
Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition 147
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes 145
Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population 145
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 143
Steatotic Liver Disease Phenotypes in the United States: The Impact of Alcohol Consumption Assessment 140
Authors' reply to Shang et al. 139
Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease 138
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population 137
Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general U.S. population 136
Serum neurofilament light chain levels are associated with all-cause mortality in the general US population 135
Low 25 (OH) vitamin D levels are associated with increased prevalence of NAFLD and significant liver fibrosis 134
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease 134
NAFLD and liver fibrosis are not associated with reduced femoral bone mineral density in the general US population 133
Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study 131
Glycated albumin is associated with all-cause and cardiovascular mortality among U.S. adults with and without diabetes: A retrospective cohort study 130
Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. women 130
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis 129
Reply [to: Use of FibroScan–AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US...] 129
Reply to "Liver fibrosis assessed by transient elastography and albuminuria" 123
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis 123
Global multi-stakeholder endorsement of the MAFLD definition 123
Comment on “An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD” 121
Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence 118
Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis 117
Readily Available Index of Insulin Sensitivity Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes 115
Non-invasive scores of liver fibrosis in morbidly obese patients 115
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes and association with micro- and macrovascular complications 112
Twenty-year trends in heart failure among U.S. adults, 1999–2018: The growing impact of obesity and diabetes 111
Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs 110
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States 110
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis 110
The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner? 106
Advances in fibrosis biomarkers in nonalcoholic fatty liver disease 104
Control of Blood Glucose and Cardiovascular Risk Profile 103
Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999-2016 101
Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD 98
Silent threats: how NAFLD and hypertension team up in young adults, and the role of sex 94
Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes 91
Prevalence of Noninvasively Detected Clinically Significant Portal Hypertension Among U.S. Adults With and Without Diabetes 89
Qualitative Properties of Circulating Fatty Acids Are Associated With MASLD: A Cross-Sectional Study From the NHANES Database 56
Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases 43
Totale 16.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.675
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021222 0 0 0 0 0 0 0 0 0 0 88 134
2021/2022741 117 88 99 42 25 52 28 35 50 62 44 99
2022/20231.240 146 226 123 108 92 228 40 71 87 26 58 35
2023/20241.236 89 42 84 102 112 216 166 53 91 53 34 194
2024/20254.090 215 404 309 233 331 220 288 121 343 517 427 682
2025/20268.189 883 717 637 902 859 410 1.182 438 640 698 823 0
Totale 16.745